PharmTech Drug Digest 11.20
|Articles|March 31, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-04-02-2014
  • Volume 10
  • Issue 4

PhRMA Launches National Campaign to Increase Diversity in Clinical Trials

Author(s)Melanie Sena

The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.

The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum have developed a national campaign to help increase diversity in clinical trials.

The I’m In campaign will raise awareness about the importance of clinical research and increase participation by diverse patient populations to help researchers develop potential new medicines. Partnerships with patient advocacy organizations, provider groups, individual physicians, clinical trials sponsors, and researchers will help to drive campaign awareness and involvement.

According to FDA, African Americans represent 12% of the US population but only 5% of clinical trial participants and Hispanics make up 16% of the population but only 1% of clinical trial participants. Inclusion of individuals of varied races, ethnicities, ages, gender, and sexual orientation in clinical trials can help to prevent disparities in the evaluation of potential new medicines.

I’m In will support the National Minority Quality Forum’s Clinical Trial Engagement Network, a solution to help accelerate the inclusion of underrepresented populations in clinical trials. Authorized users will be able to identify potential clinical trial participants by using zip code level mapping of disease clusters and simultaneously identifying and connecting points of care and community resources that can assist with site selection and patient recruitment.

Source: Pharmaceutical Research and Manufacturers of America


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.